(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.36%) $78.10
(0.41%) $2.22
(-0.32%) $2 316.80
(-0.69%) $27.36
(-0.16%) $986.80
(0.15%) $0.931
(0.41%) $10.94
(0.14%) $0.801
(0.01%) $91.45
Quarter results tomorrow
(bmo 2024-05-09)
Expected move: +/- 0.00%
-0.92% ¥ 1 608.00
Live Chart Being Loaded With Signals
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally...
Stats | |
---|---|
Volumen de hoy | 2 400.00 |
Volumen promedio | 4 326.00 |
Capitalización de mercado | 5.80B |
EPS | ¥0 ( 2024-01-30 ) |
Próxima fecha de ganancias | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -24.13 |
ATR14 | ¥0 (0.00%) |
Nippon Chemiphar Co., Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nippon Chemiphar Co., Finanzas
Annual | 2022 |
Ingresos: | ¥31.56B |
Beneficio Bruto: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Ingresos: | ¥31.56B |
Beneficio Bruto: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Ingresos: | ¥32.51B |
Beneficio Bruto: | ¥9.07B (27.91 %) |
EPS: | ¥194.33 |
FY | 2021 |
Ingresos: | ¥31.54B |
Beneficio Bruto: | ¥11.44B (36.28 %) |
EPS: | ¥137.75 |
Financial Reports:
No articles found.
Nippon Chemiphar Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥30.00 | 2008-03-26 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | ¥1 040.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 5.79 | |
Div.Growth Potential Score | 1.529 | |
Div. Directional Score | 3.66 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8377.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7775.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6941.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6301.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5020.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4224.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3443.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2587.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9474.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8101.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.00787 | 1.500 | -0.157 | -0.236 | [0 - 0.5] |
returnOnAssetsTTM | -0.00473 | 1.200 | -0.158 | -0.189 | [0 - 0.3] |
returnOnEquityTTM | -0.0130 | 1.500 | -1.255 | -1.883 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.43 | 0.800 | 2.86 | 2.29 | [1 - 3] |
quickRatioTTM | 1.563 | 0.800 | 5.51 | 4.41 | [0.8 - 2.5] |
cashRatioTTM | 0.747 | 1.500 | 6.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.344 | -1.500 | 4.27 | -6.41 | [0 - 0.6] |
interestCoverageTTM | -3.58 | 1.000 | -2.44 | -2.44 | [3 - 30] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.934 | -1.500 | 6.26 | -9.40 | [0 - 2.5] |
grossProfitMarginTTM | 0.251 | 1.000 | 9.15 | 9.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0153 | 1.000 | -2.31 | -2.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.164 | 1.000 | -0.199 | -0.199 | [0.2 - 2] |
assetTurnoverTTM | 0.601 | 0.800 | 9.33 | 7.46 | [0.5 - 2] |
Total Score | 5.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -24.11 | 1.000 | -2.54 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0130 | 2.50 | -0.807 | -1.883 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.589 | 1.500 | -7.26 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0939 | 1.000 | -0.153 | 0 | [0.1 - 0.5] |
Total Score | 1.529 |
Nippon Chemiphar Co.,
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico